Introduction
Transient cerebral ischaemic attacks (TIAs) may be the first clinical warning of an impending major stroke (Acheson and Hutchinson, 1971) . Since TIAs are probably caused by platelet emboli, drugs which reduce the tendency of platelets to aggregate into thrombi (Turpie and Hirsch, 1978) Patients with a history of having experienced one or more TIAs before the one which led to acceptance into the trial had a rather greater tendency to have recurrences during the trial (5 out of 11) compared with those in whom this had been the first attack (8 out of 24).
Carotid bruits
Bruits were heard over the carotids in 25% of the patients. They were not present in those with a major complication but were present in similar proportion in those with and without recurrent TIAs.
Other factors
The sex ratio remained similar in the sub-groups of those who completed the trial. However all the major complications occurred in men. Blood pressure did not appear to influence outcome. This was not surprising since uncontrolled hypertension (diastolic >110 mmHg) was a bar to entry into the trial.
Follow-up study (Table 3) Thirty-seven patients were available for follow-up, comprising 35 who completed the 8-month trial period, and the 2 patients with non-fatal strokes who had previously been withdrawn from the study following this complication. Seven of the 13 patients who had TIAs during the sulphinpyrazone trial had further neurological events, 2 died from a stroke and 5 continued to have TIAs. In contrast, of the 22 patients who had no neurological episodes during the trial, 20 continued free of neurological episodes, although one developed cardiac failure and died, and one patient died after a fall. Only one experienced TIAs for the first time after the end of the drug trial and another had a non-fatal stroke. Thus, the risk of having further neurological events is significantly less (P < 0-01) amongst patients who do not have a recurrence during the 6-8 months after the initial episode.
Only 9 of the 37 patients followed-up had continued taking sulphinpyrazone after the initial study. Of the 2 patients who had non-fatal strokes during the drug study, one had died during the follow-up period while the other continued to have TIAs despite sulphinpyrazone therapy.
Discussion
This study showed that on entering the trial the greatest risk of developing a further neurological episode occurred in the first 4 months (3 out of 4 strokes, and all 13 patients with TIAs). Furthermore This study clearly shows that the probability of the recurrence of TIAs is greater in the first 4 months following an attack, but there was little evidence that sulphinpyrazone was of any value in preventing them.
